News

New research: Hospitals risk millions from failure to provide consumer-friendly mobile apps. How to achieve exceptional consumer experience.

Broader exchange of ideas for diabetes health management and related programs may result in more efficient community-based programs with a wider impact.

Pharmaceutical companies are battling state legislation that would require state programs such as Medicaid to pay no more than other Federal government programs for drugs.

Independence reaches a deal with NantHealth to cover next-generation whole genome sequences for a variety of cancers.

Analysts ponder what Aetna’s leave from AHIP means for the industry and the powerhouse trade association.

After a death and a hospitalized patient, FDA is cautioning that differences in dosing regimens between the 2 oral formulations of Merck’s antifungal drug Noxafil (posaconazole) have resulted in dosing errors.

New initiative poised to be a model for health plan providers to foster improved collaboration between pharmacists and physicians.

Don't let your healthcare organization's information be compromised. Watch out for these common mistakes.

Innovation will be necessary to compete for consumers in the new market environment. Using data effectively can help plans stand out.

Gilead Sciences, which already makes the leading hepatitis C drugs Harvoni and Sovaldi, recently received priority review from FDA for a new Hepatitis C combination drug.

The Commonwealth Fund examined the effects of the ACA’s Medicaid expansion on low income adults in three states that took different approaches to the law. Here’s what they found.

While forming risk-based entities among Medicaid providers could be an effective way to better manage the care of low-income populations, the risk of unintended consequences cannot be ignored. A key hedge against these consequences is better use of patient data.

After much angst and several delays, the healthcare industry recently completed the ICD-10 transition, but was it really necessary?

Coordination is key in improving adherence and outcomes in patients with chronic conditions. Here’s how.

Amicable resolution between FDA and Pacira Pharmaceuticals, Inc., which reaffirms the broad indication for Exparel (bupivacaine liposome injectable suspension).

Hospital pharmacies need to check their supplies of norepinephrine after PharMEDium Services in Lake Forest, Ill., voluntarily recalled several lots of Norepinephrine Bitartrate. The product is used to control blood pressure in certain acute hypotensive states.

What reimbursement changes can healthcare executives expect in 2016? Three experts weigh in.

Change is in the air as a new year begins. These five trends will continue to gain momentum in the healthcare industry.

There's good news in efforts to combat HIV/AIDs and hepatitis C (hep C, HCV). Some feel, however, that policymakers could do more to prioritize resources to fully eradicate the diseases.

The changing healthcare industry is leading organizations to prioritize new skill sets during recruitment efforts.

Tips to help healthcare executives present their most authentic selves during remote interviews.

The solution to succeeding in value-based reimbursement models is to start inside the hospital with high acuity patients and build the systems that support them.

Optimism exists for biosimilars in the United States, but questions regarding FDA approval and reimbursement remain.

Some providers and payers are hesitant to jump on board with telemedicine, but others say it the benefits are clear.

In late December, FDA approved AstraZeneca’s Zurampic (lesinurad) 200-mg tablets in combination with a xanthine oxidase inhibitor (XOI) for high levels of uric acid in the blood (hyperuricemia) associated with gout.

FDA approved expanded age indication for Human Papillomavirus 9-valent Vaccine, Recombinant (Gardasil 9, Merck) in males.

Survey reveals how size impacts health plan challenges, priorities, outlook, and technology use.